Sunday, December 04, 2016 12:17:35 PM
Extracorporeal blood purification techniques (EBTs) are emerging as beneficial interventions in the management of sepsis. Although the combination of different EBTs has also been suggested as a potentially effective approach in the early phases of sepsis [1, 2], no data are available for pediatric septic shock. We reported a case of refractory septic shock in a 12-year-old girl, with a clinical history of acute lymphatic leukemia and recent chemotherapy, who was admitted to the emergency department (ED) because of fever and fatigue. In the ED ward, mean arterial pressure (MAP) was below 50 mmHg and did not improve after initial fluid resuscitation (20 ml/kg). Empiric antimicrobial therapy was initiated and the patient was admitted to the pediatric intensive care unit. Because of severe persistent hypotension with arterial lactate concentrations of 74 mg/dl, epinephrine and norepinephrine were initiated at 0.2 µg/kg/min and 0.08 µg/kg/min, respectively. Six hours after admission, the patient remained severely hypotensive (MAP of 45 mmHg) despite fluid and vasopressor therapy and low-dose hydrocortisone administration. In the absence of oliguria, continuous renal replacement therapy (CRRT) was started (continuous venovenous hemodiafiltration modality; effluent of 35–40 ml/kg.h)
with a high cutoff (HCO) filter (Septex®) in combination with a cartridge column (CC; Cytosorb®). A significant reduction of vasopressor doses was observed 48 hours after the initiation of EBT (Fig. 1). A similar positive trend was observed for lactate (74 vs 32 mg/dl) and procalcitonin (65 vs 18 ng/ml) concentrations. This “hybrid” EBT was continued for 72 hours without adverse events. The patient was successfully discharged after 10 days. The blood cultures yielded Klebsiella pneumonia, related to a percutaneously inserted central line infection. In this case, the benefits of CRRT in the management of fluid overload and metabolic abnormalities in children with septic shock were associated with the immune-modulatory effects of EBTs. HCO filters are characterized by large pore size (e.g., cutoff value of 70 kDa) with improved convective clearance of middle molecular weight molecules, such as cytokines [3]. CCs have a large surface area that could also directly adsorb and clear inflammatory mediators [4]. The combination of HCO-CRRT and CC might have a synergistic effect in this setting [5]; this association has not yet been explored in the treatment of pediatric septic shock. Further studies are needed to assess the feasibility as well as the optimal timing of initiation of such an approach in children suffering from septic shock.
Recent CTSO News
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/26/2024 11:00:00 AM
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:31:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:30:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 02:15:22 PM
- CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering • GlobeNewswire Inc. • 12/13/2023 02:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/11/2023 09:10:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:10:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:20:25 PM
- CytoSorbents Reports Third Quarter 2023 Financial and Operational Results • GlobeNewswire Inc. • 11/09/2023 09:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:10:54 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM